Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2023-05-22 Major Shareholding Noti…
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. It details changes in share ownership by a major shareholder (Jung Jong Sun) and related parties in the company Syntekabio. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks significant ownership thresholds and changes in equity stakes.
2023-05-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share acquisition (장내매수) by a director (Jung Jong Sun) of Syntekabio. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2023-05-22 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'SyntekaBio' (신테카바이오) covering the period from 2023.01.01 to 2023.03.31. It contains detailed financial information, business descriptions, and management discussions, which is characteristic of an interim/quarterly financial report. It is not a mere announcement or certification, as it provides substantive financial data and operational details. Q1 2023
2023-05-15 Korean
[기재정정]주요사항보고서(유형자산양수결정)
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) by Syntekabio. It is titled 'Correction Report' (정정신고) regarding a 'Decision to Acquire Tangible Assets' (유형자산 양수 결정). This is a standard corporate disclosure document (Major Matter Report) used in the Korean market to update shareholders on material business events, such as property acquisitions, and does not fit into specific categories like earnings releases or annual reports. Therefore, it is classified as a Regulatory Filing (RNS).
2023-04-19 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the number of shares, exercise price, exercise period, and the list of recipients (directors and auditors). This type of disclosure regarding equity-based compensation and capital changes is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (which is for personal trades) or DEF 14A (which is for executive compensation reports).
2023-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과) for Syntekabio. It details the approval of financial statements, board/auditor appointments, and other resolutions passed during the meeting. This falls under the category of Declaration of Voting Results & Voting Rights Announcements, as it confirms the outcomes of the shareholder votes.
2023-03-31 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.